252 related articles for article (PubMed ID: 30405416)
1. Polypharmacology or Promiscuity? Structural Interactions of Resveratrol With Its Bandwagon of Targets.
Saqib U; Kelley TT; Panguluri SK; Liu D; Savai R; Baig MS; Schürer SC
Front Pharmacol; 2018; 9():1201. PubMed ID: 30405416
[TBL] [Abstract][Full Text] [Related]
2. Polypharmacology: The science of multi-targeting molecules.
Kabir A; Muth A
Pharmacol Res; 2022 Feb; 176():106055. PubMed ID: 34990865
[TBL] [Abstract][Full Text] [Related]
3. Identification of Target Associations for Polypharmacology from Analysis of Crystallographic Ligands of the Protein Data Bank.
Pinzi L; Rastelli G
J Chem Inf Model; 2020 Jan; 60(1):372-390. PubMed ID: 31800237
[TBL] [Abstract][Full Text] [Related]
4. Data structures for computational compound promiscuity analysis and exemplary applications to inhibitors of the human kinome.
Miljković F; Bajorath J
J Comput Aided Mol Des; 2020 Jan; 34(1):1-10. PubMed ID: 31792884
[TBL] [Abstract][Full Text] [Related]
5. Drug Promiscuity in PDB: Protein Binding Site Similarity Is Key.
Haupt VJ; Daminelli S; Schroeder M
PLoS One; 2013; 8(6):e65894. PubMed ID: 23805191
[TBL] [Abstract][Full Text] [Related]
6. Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence.
Tomé-Carneiro J; Larrosa M; González-Sarrías A; Tomás-Barberán FA; García-Conesa MT; Espín JC
Curr Pharm Des; 2013; 19(34):6064-93. PubMed ID: 23448440
[TBL] [Abstract][Full Text] [Related]
7. Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery.
Ravikumar B; Aittokallio T
Expert Opin Drug Discov; 2018 Feb; 13(2):179-192. PubMed ID: 29233023
[TBL] [Abstract][Full Text] [Related]
8. Aza-derivatives of resveratrol are potent macrophage migration inhibitory factor inhibitors.
Fujita Y; Islam R; Sakai K; Kaneda H; Kudo K; Tamura D; Aomatsu K; Nagai T; Kimura H; Matsumoto K; de Velasco MA; Arao T; Okawara T; Nishio K
Invest New Drugs; 2012 Oct; 30(5):1878-86. PubMed ID: 21912888
[TBL] [Abstract][Full Text] [Related]
9. Network Pharmacology-Based and Molecular Docking Analysis of Resveratrol's Pharmacological Effects on Type I Endometrial Cancer.
Zhong Z; Guo X; Zheng Y
Anticancer Agents Med Chem; 2022; 22(10):1933-1944. PubMed ID: 34773964
[TBL] [Abstract][Full Text] [Related]
10. Exploration of the mechanism of traditional Chinese medicine by AI approach using unsupervised machine learning for cellular functional similarity of compounds in heterogeneous networks, XiaoErFuPi granules as an example.
Guo F; Tang X; Zhang W; Wei J; Tang S; Wu H; Yang H
Pharmacol Res; 2020 Oct; 160():105077. PubMed ID: 32687952
[TBL] [Abstract][Full Text] [Related]
11. Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective.
Zhang W; Bai Y; Wang Y; Xiao W
Curr Pharm Des; 2016; 22(21):3171-81. PubMed ID: 26907941
[TBL] [Abstract][Full Text] [Related]
12. High Impact: The Role of Promiscuous Binding Sites in Polypharmacology.
Cerisier N; Petitjean M; Regad L; Bayard Q; Réau M; Badel A; Camproux AC
Molecules; 2019 Jul; 24(14):. PubMed ID: 31295958
[TBL] [Abstract][Full Text] [Related]
13. Drug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening Methodologies.
Nikolic K; Mavridis L; Djikic T; Vucicevic J; Agbaba D; Yelekci K; Mitchell JB
Front Neurosci; 2016; 10():265. PubMed ID: 27375423
[TBL] [Abstract][Full Text] [Related]
14. Drugs Polypharmacology by In Silico Methods: New Opportunities in Drug Discovery.
Lauria A; Bonsignore R; Bartolotta R; Perricone U; Martorana A; Gentile C
Curr Pharm Des; 2016; 22(21):3073-81. PubMed ID: 26907944
[TBL] [Abstract][Full Text] [Related]
15. Polypharmacology: challenges and opportunities in drug discovery.
Anighoro A; Bajorath J; Rastelli G
J Med Chem; 2014 Oct; 57(19):7874-87. PubMed ID: 24946140
[TBL] [Abstract][Full Text] [Related]
16. Polypharmacology - foe or friend?
Peters JU
J Med Chem; 2013 Nov; 56(22):8955-71. PubMed ID: 23919353
[TBL] [Abstract][Full Text] [Related]
17. Updates on drug-target network; facilitating polypharmacology and data integration by growth of DrugBank database.
Barneh F; Jafari M; Mirzaie M
Brief Bioinform; 2016 Nov; 17(6):1070-1080. PubMed ID: 26490381
[TBL] [Abstract][Full Text] [Related]
18. Structure-Based Kinase Profiling To Understand the Polypharmacological Behavior of Therapeutic Molecules.
Dutta D; Das R; Mandal C; Mandal C
J Chem Inf Model; 2018 Jan; 58(1):68-89. PubMed ID: 29243930
[TBL] [Abstract][Full Text] [Related]
19. Exploring Polypharmacology in Drug Discovery and Repurposing Using the CANDO Platform.
Chopra G; Samudrala R
Curr Pharm Des; 2016; 22(21):3109-23. PubMed ID: 27013226
[TBL] [Abstract][Full Text] [Related]
20. Modeling Polypharmacological Profiles by Affinity Fingerprinting.
Peragovics A; Simon Z; Malnasi-Csizmadia A; Bender A
Curr Pharm Des; 2016; 22(46):6885-6894. PubMed ID: 27587199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
